Skip navigation
Dubious Diagnosis
Article

Dubious Diagnosis

A war on “prediabetes” has created millions of new patients and a tempting opportunity for pharma. But how real is the condition?

Science, 2019

auto-generated audio
auto-generated audio

Editorial Rating

9

Qualities

  • Controversial
  • Scientific
  • Eye Opening

Recommendation

At the crossroads of consumer fear and medical authority, there is a land ripe with opportunities for specialty practitioners and the drug companies that love them. “Prediabetes” is a mischievous little diagnosis that remains unrecognized by most international diabetes organizations, but in the United States the number of people with the diagnosis grows at a rate similar to the growth of the bank accounts of the American Diabetes Association’s resident experts. This Science article provides the minimum-effective dose of rage against the medical-pharmaceutical complex.

Take-Aways

  • Drug companies give huge sums of money to the specialty doctors who prescribe their drugs in standard treatment protocols.
  • The A1c test is used to diagnose prediabetes, but standards are different depending on which country you’re in.
  • Many of the doctors who set the American Diabetes Association’s (ADA) treatment standards have conflicts of interest.

About the Author

Charles Piller is an investigative journalist for Science. He’s also written about public health for STAT, the Los Angeles Times and The Sacramento Bee.


More on this topic

Learners who read this summary also read